Zhong, Feisheng
Wu, Xiaolong
Yang, Ruirui
Li, Xutong
Wang, Dingyan
Fu, Zunyun
Liu, Xiaohong
Wan, XiaoZhe
Yang, Tianbiao
Fan, Zisheng
Zhang, Yinghui
Luo, Xiaomin
Chen, Kaixian
Zhang, Sulin http://orcid.org/0000-0002-9167-4689
Jiang, Hualiang http://orcid.org/0000-0003-0656-6315
Zheng, Mingyue http://orcid.org/0000-0002-3323-3092
Article History
Received: 4 August 2021
Accepted: 8 September 2021
First Online: 22 October 2021
Declarations
: We gratefully acknowledge financial support from the National Natural Science Foundation of China (81773634 to M.Z., 81903639 to S.Z.), National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program”, China (2018ZX09711002 to H.J.), “Personalized Medicines—Molecular Signature-based Drug Discovery and Development”, Strategic Priority Research Program of the Chinese Academy of Sciences (XDA12050201 to M.Z.) and Shanghai Sailing Program (19YF1457800 to S.Z.).
: We do not compete for commercial interests as defined by Protein & Cell.
: The authors declare that all data supporting the findings of this study are available publicly. Both the LINCS phase I L1000 dataset (GSE92742, 2012-2015) and the LINCS phase II L1000 dataset (GSE70138, 2015-2020) were downloaded from the Gene Expression Omnibus (GEO) provided by the Broad Institute. The protein–protein interactions (v11.0) were available at ExternalRef removed. The data set for modeling can be available at ExternalRef removed. The code can be freely available at ExternalRef removed, under Apache 2.0 license.
: M.Z. and H.J. conceived the project. S.Z. designed the experimental validation studies. F.Z. implemented the SGCN model. F.Z. and X.W. conducted computational analysis of transcriptional data. F.Z., X.W., X.L., D.W., Z.F., X.L. and K.C. collected and analyzed the data. R.Y., Z.F., and S.Z. performed <i>in vitro</i> experiments. F.Z., X.W., S.Z. and M.Z. wrote the paper. All authors discussed the results and commented on the manuscript.